retatrutide phase 2 results 2024 2025 press release Side Effects: Muscle Loss, Dosing Risks and Protocol Eli Lilly's retatrutide shows promising

Pregnant or Breastfeeding Women: This product is not recommended for use during pregnancy or while breastfeeding unless prescribed by a doctor

Promisingly, this conjugate did not have off-target effects in female mice

You do not qualify at BMI 25 or 26 under any FDA-approved indication

JCI Insight 7:863

The FDA warns that both CJC-1295 and ipamorelin carry risks of immunogenicity (triggering immune responses) and cardiovascular effects, including "increased heart rate and systemic vasodilatory reaction." One clinical trial of CJC-1295 was discontinued following a participants death, though the attending physician believed the event was "unrelated to treatment." Neither CJC-1295 nor ipamorelin is FDA-approved